保妇康栓联合辛复宁治疗HPV感染患者的疗效及作用机制  

Efficacy and Mechanism of Baofukang Suppository Combined with Xinfuning in the Treatment of Patients with HPV infection

作　　者：成翔燕[1] 王晓燕[1] 钱小红[2] CHENG Xiang-yan;WANG Xiao-yan;QIAN Xiao-hong(Department of Obstetrics and Gynecology,Nantong Third People′s Hospital,Nantong Third Hospital Affiliated to Nantong University,Nantong Jiangsu 226000;Operating Room,Nantong Third People′s Hospital,Nantong Third Hospital Affiliated to Nantong University,Nantong Jiangsu 226000)

机构地区：[1]江苏省南通市第三人民医院,南通大学附属南通第三医院妇产科,江苏南通226000 [2]江苏省南通市第三人民医院,南通大学附属南通第三医院手术室,江苏南通226000

出　　处：《世界中西医结合杂志》2022年第11期2255-2259,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：南通市卫生健康委员会课题(QB2019008)。

摘　　要：目的观察人乳头瘤病毒(Human papillomavirus,HPV)感染患者采用保妇康栓联合辛复宁(重组人干扰素α2b阴道泡腾胶囊)治疗的临床效果,并探讨其可能作用机制。方法选取2019年6月—2020年6月期间江苏省南通市第三人民医院,南通大学附属南通第三医院门诊就诊的HPV感染患者198例,根据随机数字表法分为治疗组和对照组,每组各99例。对照组给予重组人干扰素α2b阴道泡腾胶囊治疗,治疗组加用保妇康栓治疗。治疗3个疗程后,观察比较两组患者临床疗效、HPV转阴率、安全性、复发率,治疗前后免疫功能[CD4^(+)、CD8^(+)、Foxp3+调节性T细胞(Tregs)、CD4^(+)/CD8^(+)、免疫球蛋白A(Immunoglobulin A,IgA)、IgM(Immunoglobulin M,IgM)IgG(Immunoglobulin G,IgG)]、炎症因子[肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)、白细胞介素-6(Interleukin-6,IL-6)、白细胞介素-8(Interleukin-8,IL-8)]水平。结果治疗后治疗组临床总有效率95.96%(95/99)优于对照组82.83%(82/99),差异有统计学意义(P<0.05);治疗组HPV转阴率94.95%(94/99)优于对照组80.81%(80/99),差异有统计学意义(P<0.05)。治疗后两组患者lgA、lgG、lgM、CD4^(+)、Foxp3+Tregs、CD4^(+)/CD8^(+)指标均较治疗前升高,CD8^(+)指标均较治疗前降低,差异有统计学意义(P<0.05);且治疗组lgA、lgG、lgM、CD4^(+)、Foxp3+Tregs、CD4^(+)/CD8^(+)指标均较对照组升高,CD8^(+)指标均较对照组降低,差异有统计学意义(P<0.05)。治疗后两组患者血清TNF-α、IL-6和IL-8水平均较治疗前降低,差异有统计学意义(P<0.05);且治疗组TNF-α、IL-6和IL-8水平均较对照组明显降低,差异有统计学意义(P<0.05)。治疗期间,两组患者不良反应发生率比较,差异无统计学意义(χ^(2)=0.336,P=0.562,P>0.05)。6个月后随访,两组患者复发率比较,差异有统计学意义(χ^(2)=4.968,P=0.026,P<0.05)。结论对于HPV感染的患者,在给予重组人干扰素α2b阴道泡腾胶囊用药的同时加以保妇康�Objective To observe the effect of Baofukang suppository combined with Xinfuning(recombinant human interferonα2 b vaginal effervescent capsules)in patients with human papillomavirus(HPV)infection and explore its possible mechanism.Methods A total of 198 patients with HPV infection who were treated in outpatient service in Nantong Third People′s Hospital from June 2019 to June 2020 were divided into a control group and an interventi on group by the random number table,with 99 patients in each group.The control group was given recombinant human interferonα2 b vaginal effervescent capsules,and the intervention group was additionally treated with Baofukang suppository.After three courses of treatment,the clinical efficacy,HPV negative conversion rate,safety,and recurrence rate of the two groups were compared.The levels of immune functions[CD4^(+),CD8^(+),Foxp3+regulatory T cells(Tregs),CD4^(+)/CD8^(+),immunoglobulin A(IgA),immunoglobulin M(IgM),and immunoglobulin G(IgG)]and inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin(IL)-6,and IL-8]of the two groups before and after treatment were compared.Results After treatment,the total effective rate and the HPV negative conversion rate of the intervention group were 95.96%(95/99)and 94.95%(94/99),respectively,which were superior to those of the control group[82.83%(82/99)and 80.81%(80/99),respectively](P<0.05).After treatment,the indexes of lgA,lgG,lgM,CD4^(+),Foxp3+Tregs,and CD4^(+)/CD8^(+)in the groups were increased,whereas the index of CD8^(+)was decreased(P<0.05).The indexes of lgA,lgG,lgM,CD4^(+),Foxp3+Tregs,and CD4^(+)/CD8^(+)in the intervention group were higher than those in the control group,and the index of CD8^(+)was lower than that in the control group(P<0.05).After treatment,the levels of serum TNF-α,IL-6,and IL-8 in the two groups were decreased(P<0.05),and the intervention group was lower than the control group(P<0.05).During treatment,there was no statistical significance in the incidence of adverse reaction between the two groups(χ^(

关 键 词：保妇康栓 辛复宁 炎症 重组人干扰素α2b阴道泡腾胶囊 人乳头瘤病毒 免疫功能 

分 类 号：R373.9[医药卫生—病原生物学] R737.33[医药卫生—基础医学]